Kiniksa Pharmaceuticals International, plc (KNSA) Gross margin 2021–2025
Kiniksa Pharmaceuticals International, plc (KNSA) gross margin by fiscal year — reported gross profit divided by reported revenue.
88.5%FY2025 · since FY2021: 76.4% → 88.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 88.5% | +2.9 pp |
| FY2024 | 85.6% | -2.0 pp |
| FY2023 | 87.6% | -2.0 pp |
| FY2022 | 89.6% | +13.2 pp |
| FY2021 | 76.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More KNSA financial trends
KNSA RevenueKNSA Net incomeKNSA Net marginKNSA Gross profitKNSA Operating incomeKNSA Operating marginKNSA Operating cash flowKNSA Free cash flowKNSA Capital expendituresKNSA Return on equityKNSA Stock buybacksKNSA Dividends paidKNSA Total assetsKNSA Total liabilitiesKNSA Shareholders’ equityKNSA overview →